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Abstract 
Background: Rheumatoid arthritis (RA) and chronic periodontitis are the most common chronic inflammatory dis-
eases with significant pathological and clinical similarities. Numerous studies have indicated a relationship between 
rheumatoid arthritis and periodontal disease. The aim of this study was to compare the TNF-α levels in saliva among 
patients with Rheumatoid arthritis (RA) and chronic periodontitis as well as healthy subjects.
Methods: One hundred and seventy-one patients were enrolled in this cross-sectional study. Fifty-seven patients 
diagnosed of RA, 57 patients with chronic periodontitis and 57 healthy subjects. These patients have been examined 
with regard to TNF-α level from salivary samples. Their teeth were examined with regard to Plaque Index , Gingival 
Index, probing depth and clinical attachment level.All patients were non-smokers.
Results: The results revealed a significant difference in all periodontal parameters among the three groups. The 
chronic periodontitis group showed a significantly higher value in all clinical periodontal parameters in comparison to 
both the RA and healthy groups. No significant difference was found between salivary TNF-α level among the three 
study groups.
Conclusions: Patients with chronic periodontitis had the highest periodontal indices. However there was no signifi-
cant difference regarding the level of salivary TNF-α. Hence, suppression of proinflammatory cytokines might prove 
beneficial in suppressing periodontal diseases among RA patients.
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Background
Periodontal diseases are destructive inflammatory condi-
tions of the hard and soft tissues surrounding the teeth 
[1].
Rheumatoid arthritis (RA) is a systemic autoimmune 
disease that affects 0.5–1.0% of the population, with 
women carrying a higher risk (3:1) of disease than men 
[2]. Both RA and periodontitis are characterized by self-
maintaining inflammation in a fluid filled compartment 
adjacent to bone, in which an inflammatory process lead 
to common clinical symptoms and, ultimately, to destruc-
tion of the adjacent bone [3]. In addition, periodontitis 
has remarkably similar cytokine profiles to RA [4]. As 
for RA, disease progression seen in chronic periodontitis 
consists of the continuing presence of high levels of pro-
inflammatory cytokines including IL-1β and TNF-α and 
low levels of anti-inflammatory cytokines like IL-10 and 
transforming growth factor-beta (TGF-β) [5, 6].
During recent years, there has been increasing evi-
dence suggesting a correlation between RA and perio-
dontitis, a number of well conducted studies have shown 
that patients with RA have an increased possibility of 
expressing mild to severe periodontitis compared with 
healthy people [7, 8].
TNF-α along with several types of inflammatory bio-
markers associated with both oral diseases, as well as sys-
temic diseases have been detected in saliva [9].
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The study carried out by Abdelsalam et  al. in 2010 in 
Sudan [10] indicated a significant relationship between 
periodontal disease and RA and highlighted the potential 
for an association between these chronic inflammatory 
conditions among the Sudanese population.
Considering these findings, there is a need to further study 
the factors that may contribute to the relationship between 
chronic periodontitis and RA. Additionally the presence of 
common underlying inflammatory pathways mediating the 
progression of periodontitis and RA would offer potentially 
important common therapeutic targets [11].
Therefore this research was designed to determine and 
compare the TNF-α level in saliva among patients with 
Rheumatoid arthritis (RA), chronic periodontitis, and 
healthy control subjects.
Methods
One hundred and seventy-one patients were enrolled in 
this cross-sectional study. Fifty-seven patients diagnosed 
of RA as defined by the American College of Rheumatol-
ogy (ACR) and the European League Against Rheuma-
tism (EULAR) classification, were invited to participate 
in this study [12].
Fifty-seven patients with chronic periodontitis based 
on the criteria defined by the American Academy of Peri-
odontology Armitage [13] and 57 healthy subjects were 
enrolled.
Rheumatoid arthritis subjects were selected from the 
common rheumatoid arthritis clinics in Khartoum State, 
while chronic periodontitis and healthy subjects were 
recruited from the periodontology departments, Faculty 
of Dentistry—University of Khartoum and Khartoum 
Dental Teaching Hospital.
Duration of RA as well as drugs used by these patients 
for the treatment of RA were recorded.
Exclusion criteria included systemic diseases that can 
affect periodontal status, smoking, antibiotic therapy 
within the last 3  months and periodontal treatment 
within the last 6  months. Additionally, subjects having 
less than 10 teeth were excluded from the study.
Data collection
Demographic data, duration of the disease since it was 
diagnosed and type of the anti-rheumatoid drug were 
taken from records of the patients at the rheumatoid 
clinics.
Periodontal examination
A calibrated examiner (periodotist Gamel EB) recorded 
all clinical periodontal indices; plaque index (PI) [14, 15], 
gingival index (GI) [16], pocket depth (PD), and CAL for 
each patient, after the collection of saliva. Measurements 
for those indices were recorded from six locations per 
tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-
lingual, mid-lingual, and disto-lingual) using Michigan O 
periodontal probe.
The clinical base line data were attached in a supple-
mentary file.
Saliva collection
Saliva samples were obtained from all subjects at the 
day of the intraoral examination. Unstimulated whole 
saliva was collected in sterile collection tubes from each 
subject between 9 and 11 a.m. according to the method 
described by Navazesh [17] as follow:
1 The patient was asked to avoid intake of any food or 
beverages (except for water) 1 h before the saliva col-
lection.
2 The patient was asked to rinse his/her mouth with 
tab water and then to take a rest for 5 min.
3 Then the patient was asked to swallow to empty his/
her mouth from saliva.
4 After that the patient was asked to sit in an upright 
position and allow saliva to accumulate in the floor 
of the mouth and spit it in graduated test tube every 
60 s.
Collected samples were put on ice immediately and 
then frozen at −80  °C until the time of analysis. Forty 
saliva samples were selected by simple randomization 
to undergo the ELISA analysis as follow; fifteen samples 
from the RA group, fifteen from patients with chronic 
periodontitis and ten samples from the control group. 
The lottery method was applied for simple randomi-
zation. TNF-α was analyzed in salivary samples using 
Biolegend’s ELISA MAX™ standard set which is a quan-
titative sandwich Enzyme-Linked Immunosorbent Assay 
(ELISA). The TNF-α level was expressed in picogram per 
milliliter (pg/ml).
Statistical analysis
Statistical Package for the Social Sciences® (SPSS) com-
puter software version 22 was used for analysis of the 
data obtained. Independent sample’s T test and one way 
ANOVA were used for comparison of means. Pearson’s 
correlation was used to correlate the quantitative varia-
bles. p value of less than 0.05 considered significant. Con-
founding variables were statistically controlled. Data was 
presented in frequencies, tables and graphs (Additional 
file 1).
Results
Fifty-seven RA patients together with 57 chronic peri-
odontitis patients and 57 healthy adult subjects par-
ticipated in the study, with a mean age approximately 
Page 3 of 6Gamel et al. BMC Res Notes  (2017) 10:34 
similar in the RA and chronic periodontitis groups 
(42.9 ± 10.3) years and (42.0 ± 10.0) years respectively. 
However, a younger age was found in the control group 
(30.51 ± 6.00) years (Fig. 1). Subjects were predominantly 
females in the three groups (Fig. 2).
The medications used by the RA patients were metho-
trexate, hydroxychloroquine, prednisolone, NSAID and 
sulphasalazine (Table 1).
Clinical periodontal measurements were analyzed in 
two steps: first, the full mouth recordings at six sites/
tooth were compared between the study groups; then the 
levels of salivary TNF-α were compared among the three 
study groups (Additional file 1).
The mean values of clinical periodontal measurements 
(PI, GI, PD and CAL) are outlined in Table 2.
The results revealed a significant difference in all perio-
dontal parameters among the three groups. The periodon-
tal disease group experienced a significantly higher values 
in all clinical periodontal parameters in comparison to the 
RA and healthy groups (p value = 0.001) (Table 2).
There was no significant correlation between the type 
of drug used for treatment of RA and the clinical attach-
ment loss (CAL) (Table  3). Additionally, no significant 
difference has been obtained when correlating the CAL 
with the disease duration (p = 0.189).
The mean level of salivary TNF-α levels in the RA 
patients were(30.80 ± 26.73) pg/ml while in the chronic 
periodontitis patients and control subjects were 
(28.70 ± 35.24) pg/ml, (35.98 ± 30.43) pg/ml respectively. 
When comparing the salivary levels of TNF-α among the 
3 study groups using one way ANOVA test, no significant 
difference was detected (p value = 0.846) (Table 4).
No significant correlation was found between the sali-
vary level of TNF-α and CAL in the chronic periodontitis 
and RA groups (Table 5).
Discussion
Rheumatoid arthritis (RA) is considered a major repre-
sentative of a large group of rheumatic diseases whose 
main manifestation is arthritis [18]. Chronic Periodon-
titis is a chronic inflammatory disease, characterized 
by tissue destruction which results from the interaction 
of microbial dental plaque with host immune defense 
mechanisms [19].
There are some similarities between the local tissue 
destruction features of RA and periodontal disease mani-
fested in active tissue destruction of both diseases by the 
presence of similar cells infiltration as well as inflamma-
tory mediators [20].
In both diseases, TNF-α contributes to the upregula-
tion of osteoclastogenesis and the of osteoblastogenesis 
[21].
The current study compared the periodontal param-
eters and the salivary level of TNF-α among RA patients, 
chronic periodontitis patients and healthy subjects. 
Additionally it correlated the level of the salivary TNF-α 
with the CAL in each group.
The results revealed a significant difference in peri-
odontal parameters (PI, GI, PD and CAL) among the 

































Fig. 2 Gender distribution among the RA, chronic periodontitis and 
control groups
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highest score detected among the chronic periodontitis 
group followed by the RA group, while the least score 
was identified among the control group.
Although increased levels of clinical attachment loss 
(CAL) may be expected in patients with RA, the long-
term usage of anti-rheumatic agents may be responsible 
for the lesser level of attachment loss among rheumatoid 
arthritis patient comparing with periodontitis patients, as 
it has been suggested that treatment of RA with disease 
modifying anti-rheumatic drugs (DMARD) improves 
their periodontal condition due to its host modulatory 
effect, thus masking the gingival inflammation and actual 
periodontal destruction. This led to reduction in the 
severity of periodontal diseases among RA group com-
paring with chronic periodontitis patients [22–24].
This finding is similar to the findings of Mirrielees et al. 
[25] who found that, the chronic periodontitis group 
had significantly higher values for all clinical periodontal 
parameters compared with the RA and healthy groups.
Moreover, when comparing the level of salivary TNF-α 
among the RA patients, chronic periodontitis patients 
and controls, the values did not show significant differ-
ences, furthermore the amount of clinical attachment 
loss among the rheumatoid arthritis and chronic peri-
odontitis groups was not correlated with salivary TNF-α 
level, supporting the idea that levels of inflammatory 
mediators in periodontitis may be influence by multiple 
factors such as remission and active period of the disease 
and local bacterial compositions [26].
Other possibility for the insignificant difference in the 
level of salivary TNF-α among the three groups and the 
absence of a correlation between the level of salivary 
TNF-α among the RA group is that, the DMARD therapy 
can influence salivary biomarkers of periodontal disease 
as well as salivary biomarker of RA patients. This reduc-
tion of the level of salivary TNF-α could be a reflection 
of reduced RA disease activity and also might affect the 
inflammatory components of periodontal disease [25].
This result agrees with the finding of other previous 
studies [24, 25, 27] however it disagrees with the results 
obtained by Kobayashi et al. [28] who found a significant 
difference in the level of serum TNF-α between the RA 
and control groups.
Table 2 Comparison of the periodontal parameters among the study groups using one way ANOVA test
One way ANOVA test performed,  p value is significant
RA Chronic periodontitis Control p value
Mean SD Mean SD Mean SD
PI 0.91 0.32 1.62 0.27 0.23 0.26 0.001
GI 0.99 0.17 1.52 0.33 0.26 0.32 0.001
PDD 0.02 0.04 0.16 0.41 0 0 0.001
CAL 0.51 0.57 0.86 0.77 0 0 0.001
Table 3 The Correlation between  the types of  the drug 
used and the Clinical Attachment loss (CAL)
N Mean SD Sig
Methotrexate 27 0.60 0.68 0.285
Non methotrexate 30 0.43 0.44
Hydroxychloroquine 44 0.50 0.56 0.832
Non hydroxychloroquine 13 0.54 0.62
Prednisolone 40 0.54 0.59 0.485
Non prednisolone 17 0.43 0.52
NSAID 5 0.57 0.51 0.815
Non NSAID 52 0.50 0.57
Sulphasalazine 4 0.49 0.56 0.953
Non sulphasalazine 53 0.51 0.57
Table 4 Comparison of  TNF-α salivary level among  the 
study groups
One way ANOVA performed, p value = 0.846, p value is not significant
TNF level N Mean SD 95% CI for mean
Lower bound Upper bound
RA 15 30.80 26.73 16.00 45.60
Chronic periodon-
titis
15 28.70 35.24 9.18 48.22
Control 10 35.98 30.43 14.21 57.74
Total 40 31.31 30.40 21.58 41.03
Table 5 Correlation between  the salivary TNF-α levels 
and CAL in the RA and chronic periodontitis groups
p value is not significant
Group Correlation Pearson’s correlation p value
RA TNF-CAL −0.212 0.447
Chronic periodontitis TNF-CAL 0.38 0.162
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The finding of the present study highlights prospects to 
consider biological therapies for periodontitis that would 
specifically target selected proinflammatory mediators 
for control in the local oral environment.
Conclusion
The present data further supports the hypothesis that 
disregulation of molecular pathways in the inflammatory 
response causes RA as well as periodontitis.
Immuno-suppressive drugs and NSAIDs decrease the 
production of inflammatory mediators in RA patients. 
Consequently without long-term NSAID suppression, 
RA patients would exhibit higher salivary amounts of 
these mediators that may possibly lead to increased peri-
odontal destruction [29].
It appears that RA and periodontitis have a significant 
difference on the clinical periodontal parameters how-
ever no significant difference was observe regarding the 
level of salivary TNF-α.
To understand further the nature and mechanisms of 
interactions between RA and periodontitis, further longi-
tudinal clinical studies are needed.
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